Cyclops®

  • Convenient
  • Reliable
  • Easy-to-use
  • Easy-to-carry
  • Hygienic
  • Less Cough

Farmaceutisch productietechnicus

PureIMS

Farmaceutisch productietechnicus

| Posted on |

Farmaceutisch productietechnicus

  PureIMS is een gespecialiseerd farmaceutisch bedrijf dat zich toelegt op de ontwikkeling en commercialisering van geneesmiddelen geschikt voor inhalatie  Om onze productie-efficiëntie te waarborgen zoeken we op korte termijn een: Farmaceutisch productietechnicus Zelfstandige medewerker die het productieteam en de apothekers ondersteunt   Belangrijkste taken en verantwoordelijkheden: Bedient en onderhoudt de apparatuur voor de productie […]

PureIMS secures a European grant to develop a new dry powder inhaler

| Posted on |

PureIMS secures a European grant to develop a new dry powder inhaler

  PureIMS receives a grant of € 41.028,58 to initiate the development of a new dry powder inhaler (DPI). This new DPI will contain an innovative dispersion mechanism to enable delivery of medicines such as antibiotics, vaccines, and biologics. Unlike current devices, it will be user-friendly and suitable for vulnerable groups like children and elderly […]

An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops

| Posted on |

An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops

Full paper: Pharmaceutics 2025, 17(9), 1149; https://doi.org/10.3390/pharmaceutics17091149 Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These […]

Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

| Posted on |

Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

EMA as well as FDA recently designated PureIMS’s colistin dry powder inhaler ‘Colistin Cyclops®’ orphan drug product for the treatment of cystic fibrosis.   Colistin Cyclops® is an orally inhaled antibiotic used for treating (chronic) Pseudomonas aeruginosa infections of the lungs. Despite the transformative potential of CFTR modulators in addressing the root causes of cystic fibrosis, […]

CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

| Posted on |

CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

Fagron and PureIMS have joined forces to make CYCLOPS® dry powder inhaler available nationwide in the Netherlands. The two Dutch pharmaceutical companies recently signed an agreement, granting Fagron the exclusive rights to organize the national distribution of PureIMS’s compounded preparations, such as an inhaled antibiotic for the treatment of pulmonary Pseudomonas aeruginosa infections caused by […]

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

| Posted on |

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

Please check out our latest poster (#708) presenting clinical study results of a head-to-head comparison between Levodopa Cyclops® and Inbrija®. Highlights are: Levodopa Cyclops® is safe and very well tolerated (no cough). Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria. Results enable abbreviated registration routes with a limited – PK-only […]

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

| Posted on |

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]